Table 2.
Baseline clinical characteristics of participants of who were randomized
| Characteristic | POWIR (N = 52) | FLEX (N = 54) |
|---|---|---|
| Mean (SD) or % of sample | Mean (SD) or % of sample | |
| Age (years) | 62.3 (6.7) | 62.2 (6.7) |
| Comorbidity index | 1.9 (1.7) | 1.6 (1.7) |
| BMI (kg/m2) | 29.5 (5.8) | 29.5 (5.6) |
| Spine (L1–L4) T-scorea | −0.52 (1.2) | −0.55 (0.99) |
| Femoral neck T-scorea | −0.96 (0.86) | −1.01 (0.82) |
| FSH (IU) | 82.3 (36.0) | 69.1 (32.0) |
| Estradiol (pg/ml) | 5.7 (2.9) | 7.6 (4.0) |
| Time since diagnosis (months) | 56.5 (39.9) | 64.5 (35.4) |
| Stage 0 (%) | 7.7% | 3.7% |
| Stage I (%) | 38.5% | 40.7% |
| Stage II (%) | 48.1% | 35.2% |
| Stage IIIa (%) | 1.9% | 9.3% |
| Received chemotherapy (%) | 61.5% | 59.3% |
| Received radiation therapy (%) | 92.3% | 83.3% |
| Currently taking AI (%) | 42.3% | 40.7% |
| Currently taking SERM (%) | 17.3% | 13.0% |
| Prior bisphosphonate use | 5.8% | 5.6% |
Data are expressed as mean (SD) for continuous data or % of sample for categorical data
AI Aromatase inhibitor, SERM selective estrogen receptor modulator
a
T-scores are reported for the lumbar spine and femoral neck. The WHO recommends the femoral neck site be used for diagnosing osteoporosis in women, but acknowledges that other skeletal sites may be considered for clinical decision making